Urothelium carcinoma
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.The subjects should fall into any of the following categories: suspected individuals with urothelial carcinoma who have hematuria or bladder irritation symptoms such as frequent urination, urgent urination, and dysuria, or those whose diagnosis of urothelial carcinoma is unknown. The population diagnosed with urothelial carcinoma for the first time, including those diagnosed with bladder cancer or upper urothelial carcinoma. People with clinical symptoms of hematuria or bladder irritation symptoms such as frequent urination, urgent urination and painful urination, and diagnosed with benign lesions of the urinary system. People who are initially diagnosed with other malignant tumors of the urinary system that are not urothelial carcinoma. 2. Voluntarily participate in this clinical trial and be able to enroll urine samples before undergoing surgical treatment. 3. The clinical background information is complete, including the basic information of the subjects (gender, age, etc.) and the background information of clinical diagnosis.
Exclusion criteria
Exclusion criteria: 1. Samples of subjects who cannot be sampled due to their own diseases, incomplete case information, and samples that cannot be traced; 2. If any of the sample collection, transportation or storage does not comply with the requirements of the evaluation reagent product manual; 3. Patients with a history of urothelial carcinoma; 4. Patients with other tumors complicated with urothelial carcinoma; 5. Subjects who the researchers consider unsuitable to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| DNA methylation analysis ;Sensitivity;Specificity; | — |
Countries
China
Contacts
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine